✨
AI Summary
- Galderma challenges Dupixent; Pfizer's Adcetris plans.
- Lilly's donanemab approval delayed; psychedelic R&D.
- Interview with BMS CDTO Greg Meyers.
Guests on This Episode
GM
Greg Meyers
2 podcast appearances